Oncology Diagnostics

Selected news for the healthcare topic - Oncology Diagnostics, collected since 10/2017. Recent stories appear in theenterpriseleader.com and slatersentinel.com. This healthcare topic shares news with Genomics, Cancer Therapy, Biocept and many others.

Please provide a valid email address.

Selected Headines

Date Headline (link) Source Relevant Snippet
1/8/2021 Biocept (NASDAQ:BIOC) Rating Lowered to Sell at Zacks Investment Research theenterpriseleader.com ... Zacks Investment Research cut shares of Biocept (NASDAQ:BIOC) from a hold rating to a sell rating in a report released on Monday, Zacks.com reports.According to Zacks, “Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. The company offers OncoCEE-BR (TM) test for ...
1/5/2021 Zacks Investment Research Downgrades Biocept (NASDAQ:BIOC) to Sell slatersentinel.com ... was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Monday, Zacks.com reports.According to Zacks, “Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. The company offers OncoCEE-BR (TM) test for ...
1/5/2021 Biocept (NASDAQ:BIOC) Downgraded to “Sell” at Zacks Investment Research zolmax.com ... Zacks Investment Research lowered shares of Biocept (NASDAQ:BIOC) from a hold rating to a sell rating in a report issued on Monday, Zacks.com reports.According to Zacks, “Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. The company offers OncoCEE-BR (TM) test for ...
1/5/2021 Biocept (NASDAQ:BIOC) Downgraded by Zacks Investment Research to "Sell" Daily Political Zacks Investment Research lowered shares of Biocept (NASDAQ:BIOC) from a hold rating to a sell report released on Monday morning, Zacks.com reports. According to Zacks, “Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. The company offers OncoCEE-BR (TM) test for breast cancer ...
12/4/2020 Onc.AI raises $6M Financing Round co-led by Blue Venture Fund and Accomplice vcaonline.com ... sciences companies), Dr. Chen Fong (Co-Chair of the Global Strategy Board at Creative Destruction Lab), and Dr. Stanley Marks (Chairman of UPMC Hillman Cancer Center). “Onc.AI is developing an innovative comprehensive approach to oncology diagnostics which can help clinicians attain the full potential of precision oncology,” said Thomas Hawes, Managing Director of the Blue Venture Fund. “We believe Onc.AI can become the standard in oncology decision support and ...
12/4/2020 Onc.AI raises $6M Financing Round co-led by Blue Venture Fund and Accomplice financialbuzz.com ... sciences companies), Dr. Chen Fong (Co-Chair of the Global Strategy Board at Creative Destruction Lab), and Dr. Stanley Marks (Chairman of UPMC Hillman Cancer Center).“Onc.AI is developing an innovative comprehensive approach to oncology diagnostics which can help clinicians attain the full potential of precision oncology,” said Thomas Hawes, Managing Director of the Blue Venture Fund. “We believe Onc.AI can become the standard in oncology decision support and ...
12/3/2020 malvern-online.com ... sciences companies), Dr. Chen Fong (Co-Chair of the Global Strategy Board at Creative Destruction Lab), and Dr. Stanley Marks (Chairman of UPMC Hillman Cancer Center).“Onc.AI is developing an innovative comprehensive approach to oncology diagnostics which can help clinicians attain the full potential of precision oncology,” said Thomas Hawes, Managing Director of the Blue Venture Fund. “We believe Onc.AI can become the standard in oncology decision support and ...
12/3/2020 Onc.AI raises $6M Financing Round co-led by Blue Venture Fund and Accomplice - Business Wire Business Wire ... sciences companies), Dr. Chen Fong (Co-Chair of the Global Strategy Board at Creative Destruction Lab), and Dr. Stanley Marks (Chairman of UPMC Hillman Cancer Center).“Onc.AI is developing an innovative comprehensive approach to oncology diagnostics which can help clinicians attain the full potential of precision oncology,” said Thomas Hawes, Managing Director of the Blue Venture Fund. “We believe Onc.AI can become the standard in oncology decision support and ...
11/3/2020 Biocept (NASDAQ:BIOC) Stock Rating Lowered by Zacks Investment Research Dakota Financial News ... Investment Research cut shares of Biocept (NASDAQ:BIOC) from a buy rating to a hold rating in a report published on Friday morning, Zacks.com reports.According to Zacks, “Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. The company offers OncoCEE-BR (TM) test for ...
11/1/2020 Zacks Investment Research Downgrades Biocept (NASDAQ:BIOC) to Hold Daily Political Biocept (NASDAQ:BIOC) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Friday, Zacks.com reports. According to Zacks, “Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. The company offers OncoCEE-BR ...
11/1/2020 Zacks Investment Research Downgrades Biocept (NASDAQ:BIOC) to Hold Ticker Report Biocept (NASDAQ:BIOC) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Friday, Zacks.com reports.According to Zacks, “Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. The company offers OncoCEE-BR ...
10/31/2020 Biocept (NASDAQ:BIOC) Cut to “Hold” at Zacks Investment Research techknowbits.com ... Investment Research cut shares of Biocept (NASDAQ:BIOC) from a buy rating to a hold rating in a research report released on Friday, Zacks.com reports.According to Zacks, “Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. The company offers OncoCEE-BR (TM) test for ...
10/30/2020 Biocept (NASDAQ:BIOC) Upgraded to Buy by Zacks Investment Research wkrb13.com upgraded shares of Biocept (NASDAQ:BIOC) from a hold rating to a buy rating in a report issued on Monday morning, Zacks.com reports. currently has $5.00 price objective on the medical research company’s stock.According to Zacks, “Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide ...
10/28/2020 Biocept (NASDAQ:BIOC) Lifted to Buy at Zacks Investment Research Dakota Financial News ... objective on the medical research company’s stock. Zacks Investment Research ‘s price objective would suggest a potential upside of 12.87% from the company’s previous close.According to Zacks, “Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. The company offers OncoCEE-BR (TM) test for ...
10/27/2020 Biocept (NASDAQ:BIOC) Downgraded by Zacks Investment Research to Hold wkrb13.com Zacks Investment Research downgraded shares of Biocept (NASDAQ:BIOC) from a buy rating to a hold rating in a research note issued to investors on Friday morning, Zacks.com reports.According to Zacks, “Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. The company offers OncoCEE ...
10/27/2020 Biocept (NASDAQ:BIOC) Upgraded to “Buy” at Zacks Investment Research Ticker Report upgraded shares of Biocept (NASDAQ:BIOC) from a hold rating to a buy rating in a report published on Monday morning, Zacks.com reports. They currently have $5.00 target price on the medical research company’s stock.According to Zacks, “Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to ...
10/27/2020 Biocept (NASDAQ:BIOC) Upgraded to “Buy” by Zacks Investment Research techknowbits.com ... price target on the medical research company’s stock. Zacks Investment Research ‘s price objective suggests a potential upside of 14.68% from the stock’s previous close.According to Zacks, “Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. The company offers OncoCEE-BR (TM) test for ...
10/27/2020 Biocept (NASDAQ:BIOC) Upgraded to “Buy” by Zacks Investment Research slatersentinel.com ... target on the medical research company’s stock. Zacks Investment Research ‘s price objective points to a potential upside of 14.68% from the stock’s previous close.According to Zacks, “Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. The company offers OncoCEE-BR (TM) test for ...
10/26/2020 Biocept (NASDAQ:BIOC) Cut to Hold at Zacks Investment Research zolmax.com ... Research cut shares of Biocept (NASDAQ:BIOC) from a buy rating to a hold rating in a research report released on Friday morning, Zacks.com reports.According to Zacks, “Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. The company offers OncoCEE-BR (TM) test for ...
10/25/2020 Zacks Investment Research Downgrades Biocept (NASDAQ:BIOC) to Hold Ticker Report Biocept (NASDAQ:BIOC) was downgraded by from a “buy” rating to a “hold” rating in a report released on Friday, Zacks.com reports.According to Zacks, “Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. The company offers OncoCEE-BR (TM) test for breast cancer. Biocept ...